roarrich
2021-12-21
Good
Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693237551,"tweetId":"693237551","gmtCreate":1640038171685,"gmtModify":1640038179193,"author":{"id":3577421737043711,"idStr":"3577421737043711","authorId":3577421737043711,"authorIdStr":"3577421737043711","name":"roarrich","avatar":"https://static.tigerbbs.com/4639d2e552942911e30f9cb5a394a1f3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693237551","repostId":1110189962,"repostType":4,"repost":{"id":"1110189962","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640009269,"share":"https://www.laohu8.com/m/news/1110189962?lang=&edition=full","pubTime":"2021-12-20 22:07","market":"us","language":"en","title":"Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1110189962","media":"Dow Jones","summary":"Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration pl","content":"<p>Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration placed a partial hold on the company's clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease.</p>\n<p>The partial, temporary suspension for patients under the age of 18 relates to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment, the company said.</p>\n<p>In premarket trading, the shares were 20% lower after closing last week at $10.62, down more than 60% since the end of last year.</p>\n<p>Bluebird said the adolescent patient is clinically well and there is no evidence of malignancy or clonal predominance.</p>\n<p>Enrollment and dosing for patients 18 and older living with sickle cell disease in its HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies, are continuing as planned, the company said.</p>\n<p>\"We have paused enrollment and treatment of patients younger than 18 in our SCD clinical program, and we will continue to work collaboratively with the FDA to understand and address their concerns,\" Chief Medical Officer Richard Colvin said.</p>\n<p>The company said it expects written questions from the FDA in early 2022 and will work quickly to respond in order to resolve the partial hold. It said it is evaluating what impact, if any, the partial clinical hold may have on its first quarter 2023 projected timing for the lovo-cel biologics license application submission.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 22:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration placed a partial hold on the company's clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease.</p>\n<p>The partial, temporary suspension for patients under the age of 18 relates to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment, the company said.</p>\n<p>In premarket trading, the shares were 20% lower after closing last week at $10.62, down more than 60% since the end of last year.</p>\n<p>Bluebird said the adolescent patient is clinically well and there is no evidence of malignancy or clonal predominance.</p>\n<p>Enrollment and dosing for patients 18 and older living with sickle cell disease in its HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies, are continuing as planned, the company said.</p>\n<p>\"We have paused enrollment and treatment of patients younger than 18 in our SCD clinical program, and we will continue to work collaboratively with the FDA to understand and address their concerns,\" Chief Medical Officer Richard Colvin said.</p>\n<p>The company said it expects written questions from the FDA in early 2022 and will work quickly to respond in order to resolve the partial hold. It said it is evaluating what impact, if any, the partial clinical hold may have on its first quarter 2023 projected timing for the lovo-cel biologics license application submission.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLUE":"bluebird bio Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110189962","content_text":"Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration placed a partial hold on the company's clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease.\nThe partial, temporary suspension for patients under the age of 18 relates to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment, the company said.\nIn premarket trading, the shares were 20% lower after closing last week at $10.62, down more than 60% since the end of last year.\nBluebird said the adolescent patient is clinically well and there is no evidence of malignancy or clonal predominance.\nEnrollment and dosing for patients 18 and older living with sickle cell disease in its HGB-206, HGB-210 and LTF-307 clinical studies, as well as follow up for treated patients of all ages in all studies, are continuing as planned, the company said.\n\"We have paused enrollment and treatment of patients younger than 18 in our SCD clinical program, and we will continue to work collaboratively with the FDA to understand and address their concerns,\" Chief Medical Officer Richard Colvin said.\nThe company said it expects written questions from the FDA in early 2022 and will work quickly to respond in order to resolve the partial hold. It said it is evaluating what impact, if any, the partial clinical hold may have on its first quarter 2023 projected timing for the lovo-cel biologics license application submission.","news_type":1},"isVote":1,"tweetType":1,"viewCount":379,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693237551"}
精彩评论